August 9, 2024 07:22 AM EDT
Deals
China
Pharma

Mer­ck pays $700M for clin­i­cal-stage CD3xCD19 bis­pe­cif­ic an­ti­body

Kyle LaHucik

Senior Reporter

Mer­ck is mak­ing its fourth ac­qui­si­tion of the year, this time buy­ing a sin­gle as­set from a Shang­hai-based can­cer drug de­vel­op­er.

The New Jer­sey phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times